The DASH after TBI study is an actively accruing , single-center , randomized , double-blinded , placebo-controlled , two-arm trial , where one group receives centrally acting sympatholytic drugs , propranolol ( 1mg intravenously every 6h for 7days ) and clonidine ( 0.1 mg per tube every 12h for 7days ) , and the other group , double placebo , within 48h of severe TBI .
